Bloodbuy, announced that it has entered into an agreement with Cerus Corporation to offer Pathogen Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT® Fibrinogen Complex, or ?IFC?) via the Bloodbuy online marketplace. Bloodbuy?s cloud-based platform connects hospitals, blood centers, and life sciences organizations using its multi-patented B2B e-commerce and computer networking technologies for blood and biological products. is a pathogen reduced blood component for fibrinogen supplementation with a 5-day post-thaw shelf life.

IFC contains fibrinogen, factor XIII, von Willebrand factor and other key clotting factors which are required for clot strength and hemostasis in patients with massive hemorrhage associated with fibrinogen deficiency. The 5-day post-thaw shelf life allows IFC to be thawed in advance and available for immediate use, and it minimizes wait times and wastage rates, addressing common inventory challenges. Maintaining an adequate blood supply and being able to respond to regional blood shortages is always a priority.

Bloodbuy enables blood centers and hospitals, via its unique online marketplace, to redistribute available blood products quickly and easily across its vast network, taking the friction out of this mission critical activity.